The for-profit joint venture, named Avobis Bio, will combine Mayo Clinic’s cell therapy and clinical expertise with Gore’s decades of experience creating and commercializing biopharmaceutical products and medical devices. Gore is perhaps best known as the developer of Gore-Tex fabric.
Avobis Bio launched with a focus on developing a stem cell-based regenerative treatment for perianal fistulas, a condition associated with Crohn’s disease that has few existing treatment options and can lead to life-threatening complications. A phase 1 clinical trial led by Mayo Clinic researchers and Gore materials science experts has already produced promising results: More than 75 percent of patients experienced healing after one year of treatment, according to the announcement.
More articles on innovation:
U of Texas to offer graduate degree for human-centered healthcare design
90% of US ‘innovation sector’ growth centered in 5 cities
Houston Methodist’s Dr. Roberta Schwartz on the ‘struggle’ of balancing data privacy with innovation: ‘It comes with friction’
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
